Clinical Report: Beyond Today’s Implants: The Next Generation of Sustained Drug Delivery
Background
Medication adherence is a significant challenge in glaucoma management, with factors such as cost, complex regimens, and cognitive decline impacting treatment consistency. Lower adherence to topical therapies is linked to faster visual field progression.
Data Highlights
Implant
IOP Reduction
Duration
Safety
iDose TR
Non-inferior to timolol
12 months
Favorable corneal endothelial safety
iDose Trex
Substantial reduction through 6 weeks
Ongoing evaluation
Pending longer-term data
PA5108
IOP reductions >20%
21 weeks
No adverse effects on corneal endothelium
OTX-TIC
Mean IOP reductions 24%-30%
6 months
No observed effect on corneal endothelium
Key Findings
Medication adherence is critical in glaucoma management, with lower adherence linked to faster disease progression.
The FDA-approved iDose TR implant demonstrated sustained IOP reduction and favorable safety through 36 months.
iDose Trex, with nearly double the drug capacity, is currently in phase 2b/3 trials.
PA5108, a biodegradable implant, showed over 20% IOP reduction in phase 2a trials with no adverse effects on corneal endothelium.
OTX-TIC demonstrated mean IOP reductions of 24%-30% through 6 months following a single administration.
Clinical Implications
Ongoing clinical trials will further clarify the roles of these new implants in practice.
Conclusion
Ongoing studies are needed to establish long-term efficacy and safety.
